Real-time enrollment status for this her2 mutation-related tumors clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 7:40 AM UTC
| NCT Number | NCT06253871 |
| Recruiting Status | Recruiting |
| Condition | HER2 Mutation-Related Tumors |
| Phase | Clinical Trial |
| Target Enrollment | 383 participants |
| Active Locations | 29 sites in the US |
| Sponsor | Iambic Therapeutics, Inc |
| Last Updated on CT.gov | June 4, 2026 (Jun 4, 2026) |
As of July 13, 2026: Clinical trial NCT06253871 is currently recruiting participants. This clinical trial study for her2 mutation-related tumors is actively seeking new participants at 29 locations across the United States. The study is sponsored by Iambic Therapeutics, Inc. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06253871 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 29 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06253871 was last updated Jun 4, 2026 (June 4, 2026). HelloStudys verifies this status automatically.